# Ajjai Alva

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ajjai-alva/

## Facts

| Field | Value |
| --- | --- |
| Citations | 17,589 |
| Field | Bladder and Urothelial Cancer Treatments |
| h-index | 60 |
| i10-index | 162 |
| Last Known Institution | University of Michigan |
| OpenAlex ID | https://openalex.org/A5044876102 |
| ORCID iD | https://orcid.org/0000-0002-1898-3522 |
| Works | 457 |

## Researcher papers

- [Integrative clinical genomics of metastatic cancer](https://scholariq.org/papers/integrative-clinical-genomics-of-metastatic-cancer/)
- [Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/kidney-cancer-version-3-2022-nccn-clinical-practice-guidelines-in-oncology/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/durvalumab-alone-and-durvalumab-plus-tremelimumab-versus-chemotherapy-in/)
- [Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-post-nephrectomy-adjuvant-therapy-for-clear-cell/)
- [NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024](https://scholariq.org/papers/nccn-guidelines-insights-kidney-cancer-version-2-2024/)
- [Amyloid-β <sup>11</sup> C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials](https://scholariq.org/papers/amyloid-sup-11-sup-c-pib-pet-imaging-results-from-2-randomized-bapineuzumab/)

## Researcher topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Urinary and Genital Oncology Studies](https://scholariq.org/topics/urinary-and-genital-oncology-studies-2/)

## Researcher university

- [University of Michigan](https://scholariq.org/institutions/university-of-michigan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.